Immuron (NASDAQ:IMRN) Stock Price Down 4% – Time to Sell?

Immuron (NASDAQ:IMRN) fell 4% on Monday . The stock traded as low as $1.15 and last traded at $1.20. 48,254 shares were traded during trading, a decline of 93% from the average session volume of 675,593 shares. The stock had previously closed at $1.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immuron in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Immuron presently has a consensus rating of “Sell”.

Immuron Stock Down 4.0%

The company’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $0.97.

Immuron (NASDAQ:IMRN) last announced its earnings results on Wednesday, February 25th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $1.40 million for the quarter.

Institutional Investors Weigh In On Immuron

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC bought a new position in Immuron (NASDAQ:IMRN) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned 0.29% of Immuron as of its most recent filing with the SEC. Institutional investors own 0.12% of the company’s stock.

Immuron Company Profile

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.